Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy
- PMID: 27242783
- PMCID: PMC4863891
- DOI: 10.3389/fimmu.2016.00176
Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy
Abstract
Receptors on T and NK cells systematically propagate highly complex signaling cascades that direct immune effector functions, leading to protective immunity. While extensive studies have delineated hundreds of signaling events that take place upon receptor engagement, the precise molecular mechanism that differentially regulates the induction or repression of a unique effector function is yet to be fully defined. Such knowledge can potentiate the tailoring of signal transductions and transform cancer immunotherapies. Targeted manipulations of signaling cascades can augment one effector function such as antitumor cytotoxicity while contain the overt generation of pro-inflammatory cytokines that contribute to treatment-related toxicity such as "cytokine storm" and "cytokine-release syndrome" or lead to autoimmune diseases. Here, we summarize how individual signaling molecules or nodes may be optimally targeted to permit selective ablation of toxic immune side effects.
Keywords: NK and T cells; NKG2D; immunotherapy; signaling; target molecules.
Figures



Similar articles
-
NKG2D receptor activation of NF-κB enhances inflammatory cytokine production in murine effector CD8(+) T cells.Mol Immunol. 2015 Feb;63(2):268-78. doi: 10.1016/j.molimm.2014.07.015. Epub 2014 Jul 31. Mol Immunol. 2015. PMID: 25089028
-
The Fyn-ADAP Axis: Cytotoxicity Versus Cytokine Production in Killer Cells.Front Immunol. 2015 Sep 16;6:472. doi: 10.3389/fimmu.2015.00472. eCollection 2015. Front Immunol. 2015. PMID: 26441977 Free PMC article. Review.
-
Clinically feasible approaches to potentiating cancer cell-based immunotherapies.Hum Vaccin Immunother. 2015;11(4):851-69. doi: 10.1080/21645515.2015.1009814. Hum Vaccin Immunother. 2015. PMID: 25933181 Free PMC article. Review.
-
CD103 or LFA-1 engagement at the immune synapse between cytotoxic T cells and tumor cells promotes maturation and regulates T-cell effector functions.Cancer Res. 2013 Jan 15;73(2):617-28. doi: 10.1158/0008-5472.CAN-12-2569. Epub 2012 Nov 27. Cancer Res. 2013. PMID: 23188505
-
Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.Cancer Res. 2006 Jun 1;66(11):5927-33. doi: 10.1158/0008-5472.CAN-06-0130. Cancer Res. 2006. PMID: 16740733
Cited by
-
Heterogeneity of Signaling Complex Nanostructure in T Cells Activated Via the T Cell Antigen Receptor.Microsc Microanal. 2023 Jul 25;29(4):1503-1522. doi: 10.1093/micmic/ozad072. Microsc Microanal. 2023. PMID: 37488826 Free PMC article.
-
IQ Domain-Containing GTPase-Activating Protein 1 Regulates Cytoskeletal Reorganization and Facilitates NKG2D-Mediated Mechanistic Target of Rapamycin Complex 1 Activation and Cytokine Gene Translation in Natural Killer Cells.Front Immunol. 2018 May 28;9:1168. doi: 10.3389/fimmu.2018.01168. eCollection 2018. Front Immunol. 2018. PMID: 29892299 Free PMC article.
-
Combined Immunodeficiency Caused by a Novel Nonsense Mutation in LCK.J Clin Immunol. 2023 Dec 19;44(1):4. doi: 10.1007/s10875-023-01614-4. J Clin Immunol. 2023. PMID: 38112969 Free PMC article.
-
Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy.Front Immunol. 2022 Mar 18;13:822298. doi: 10.3389/fimmu.2022.822298. eCollection 2022. Front Immunol. 2022. PMID: 35371071 Free PMC article. Review.
-
Circulating immune cells exhibit distinct traits linked to metastatic burden in breast cancer.Breast Cancer Res. 2025 May 8;27(1):73. doi: 10.1186/s13058-025-01982-2. Breast Cancer Res. 2025. PMID: 40340807 Free PMC article.
References
-
- Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov (2013) 3:388–98.10.1158/2159-8290.CD-12-0548 - DOI - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources